RELATIVITY-047: Phase II/III Trial of First-line Relatlimab + Nivolumab vs Nivolumab Alone in Advanced Melanoma

Source: 2021 ASCO Virtual Annual Meeting*
Download Slideset
June 4-8, 2021; Online at https://conferences.asco.org/am
Dual LAG-3 and PD-1 inhibition with a fixed-dose combination of relatlimab + nivolumab demonstrated superior PFS compared with nivolumab alone in patients with advanced melanoma.
Format: Microsoft PowerPoint (.ppt)
File Size: 338 KB
Released: June 7, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings